{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifcdzld7bo4kt4qkxiby3bbfzawcdhcgq3ysu2nh6fmcefw3y5hbe",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mgyeyeyvek42"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiafl4dy6pxw2czzzomfgtfgniixdalyzsarap4a27bsec7wzxujim"
    },
    "mimeType": "image/jpeg",
    "size": 104088
  },
  "path": "/news/2026-03-roflumilast-cream-term-safety-efficacy.html",
  "publishedAt": "2026-03-13T22:20:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "For children aged 2 to 5 years with atopic dermatitis (AD), roflumilast cream 0.05% has a favorable long-term safety profile and efficacy for up to 56 weeks, according to a study published online March 8 in Pediatric Dermatology.",
  "title": "Roflumilast cream has long-term safety, efficacy in young children"
}